Yazar "Yamazhan, Tansu" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe A national multicenter study on initial antiviral treatment preferences on chronic hepatitis B: Entecavir versus Tenofovir disoproxil fumarate(Elsevier, 2024) Yamazhan, Tansu; Zerdali, Esra; Önlen, Yusuf; Tosun, Selma; Günal, Özgür; Batırel, Ayşe; Hasanoğlu, İmran; Kaya, Selçuk; Alkan, Sevil[Anstract Not Available]Öğe Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients(Elsevier, 2022) Guner, Rahmet; Yoruk, Gulsen; Karabay, Oguz; Yamazhan, Tansu; Baykam, Nurcan; Yildirim, Mustafa; Ince, Nevin[Anstract Not Available]Öğe Switching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey(Wiley, 2021) Tabak, Fehmi; Yörük, Gülşen; Köksal, İftihar; Erdem, Hazal; Yıldız, Dilek; İnce, Nevin; Yamazhan, Tansu; Sume, Serkan; Batırel, Ayşe; Günal, Özgür; Yıldız, İlknur Esen; Sırmatel, Fatma; Koç, Meliha Merih; Çeken, Sabahat; Bozkurt, İlkay; Görenek, Levent; Şener, Alper; Köse, Şükran; Türker, Kamuran; İnan, Dilara; Karabay, Oğuz; Güner, RahmetTenofovir alafenamide (TAF) is a new prodrug of tenofovir used for the treatment of HIV-1 and HBV infections. It provides more efficient intracellular tenofovir concentrations at a relatively lower dose than provided by tenofovir disoproxil fumarate (TDF). TAF is expected to have efficacy similar to that of TDF with improved safety profile.
